Denali Therapeutics Inc. Share Price Sao Paulo
Stocks
D2NL34
BRD2NLBDR008
Biotechnology & Medical Research
|
Market Closed -
Sao Paulo
11:34:39 13/07/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 27.06 BRL | -1.31% |
|
-.--% | +25.57% |
| 25/08 | B. Riley Adjusts Denali Therapeutics Price Target to $35 From $30, Maintains Buy Rating | MT |
| 24/08 | FDA places clinical hold on Regenxbio's gene therapy for Hunter Syndrome | RE |
| Market Cap | 371.88Cr 1.91TCr 320.79Cr 301.75Cr 274.9Cr 516.95Cr 35TCr 519.75Cr 3.57TCr 1.39TCr 18TCr 1.4TCr 1.37TCr 60TCr | P/E 2026 * |
-10x | P/E 2027 * | -10.1x |
|---|---|---|---|---|---|
| Enterprise Value | 301.04Cr 1.55TCr 259.68Cr 244.27Cr 222.53Cr 418.47Cr 29TCr 420.74Cr 2.89TCr 1.12TCr 15TCr 1.13TCr 1.11TCr 48TCr | EV / Sales 2026 * |
59.9x | EV / Sales 2027 * | 23.4x |
| Free-Float |
90.03% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript : Denali Therapeutics Inc.
| 1 day | -1.31% | ||
| 3 months | +31.61% | ||
| 6 months | +21.95% | ||
| Current year | +25.57% |
| Current year | 19.44 |  | 27.42 |
| 1 year | 13.5 | | 27.42 |
| 3 years | 13.48 | | 36.2 |
| 5 years | 13.48 | | 40.04 |
| 10 years | 13.48 | | 40.04 |
| Manager | Title | Age | Since |
|---|---|---|---|
Alexander Schuth
DFI | Director of Finance/CFO | 52 | 01/05/2022 |
Ryan Watts
CEO | Chief Executive Officer | 50 | 01/08/2015 |
Peter Chin
CTO | Chief Tech/Sci/R&D Officer | 58 | 06/11/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Ryan Watts
BRD | Director/Board Member | 50 | 01/03/2015 |
Jay Flatley
BRD | Director/Board Member | 73 | 01/04/2015 |
David Schenkein
BRD | Director/Board Member | 68 | 01/04/2015 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.31% | -.--% | - | - | 371.88Cr | |
| -0.25% | -4.10% | +38.38% | +92.61% | 6.82TCr | |
| +1.21% | +0.80% | +46.29% | +85.32% | 6.42TCr | |
| -0.25% | -1.92% | -10.72% | +436.70% | 2.65TCr | |
| +0.33% | -10.61% | +1.95% | -16.27% | 2.56TCr | |
| +1.18% | -2.23% | +30.87% | -19.04% | 1.99TCr | |
| -6.09% | -12.08% | +226.11% | +375.00% | 1.71TCr | |
| +0.24% | -5.67% | -1.52% | +532.32% | 1.49TCr | |
| +4.12% | +0.30% | +52.03% | +150.18% | 1.41TCr | |
| -0.24% | +5.18% | +23.04% | +190.97% | 1.24TCr | |
| Average | -0.11% | -3.92% | +45.16% | +203.09% | 2.92TCr | |
| Weighted average by Cap. | +0.13% | -3.22% | +41.21% | +157.58% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 5.03Cr 26Cr 4.34Cr 4.08Cr 3.71Cr 6.99Cr 476.95Cr 7.02Cr 48Cr 19Cr 242.62Cr 19Cr 18Cr 804.47Cr | 13Cr 65Cr 11Cr 10Cr 9.38Cr 18Cr 1.2TCr 18Cr 121.71Cr 47Cr 612.56Cr 48Cr 47Cr 2.03TCr |
| Net income | -45Cr -233.91Cr -39Cr -37Cr -34Cr -63Cr -4.31TCr -64Cr -435.94Cr -169.68Cr -2.19TCr -170.63Cr -166.93Cr -7.27TCr | -45Cr -232.93Cr -39Cr -37Cr -33Cr -63Cr -4.29TCr -63Cr -434.1Cr -168.96Cr -2.18TCr -169.91Cr -166.23Cr -7.24TCr |
| Net Debt | -71Cr -364.62Cr -61Cr -57Cr -52Cr -98Cr -6.72TCr -99Cr -679.54Cr -264.49Cr -3.42TCr -265.97Cr -260.21Cr -11TCr | -75Cr -385.35Cr -65Cr -61Cr -55Cr -104.07Cr -7.11TCr -104.64Cr -718.17Cr -279.53Cr -3.61TCr -281.09Cr -275Cr -12TCr |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- DNLI Stock
- D2NL34 Stock
Select your edition
All financial news and data tailored to specific country editions
